Zacks Investment Research on MSN
Will Regeneron (REGN) beat estimates again in its next earnings report?
If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...
Did Novartis break U.S. antitrust laws in the storied Eylea-Lucentis rivalry? Thanks to an appeals court ruling, Regeneron has another chance to lay out its argument. The U.S. Court of Appeals for the ...
Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a ...
On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29. The company reported sales of $3.79 ...
Regeneron reported Q4 2024 earnings today - revenues were up 10% YoY to $3.79bn. Full-year revenues were up 8% to $14.2bn. Q4 GAAP EPS at $8.06, and $38 adj. full-year. The company declared its ...
Regeneron Pharmaceuticals, a company that has been analyzing genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million ...
Regeneron (NASDAQ:REGN) Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in ...
Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price, ...
Regeneron Pharmaceuticals reported strong Q4/2023 earnings, exceeding expectations and showing impressive growth from Dupixent and Libtayo. The company's next generation of blockbuster drugs are ...
In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware has ...
Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results